Last updated on June 2019

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Brief description of study

The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat to pembrolizumab can be more effective for patients with lymphoma than either drug alone.

Clinical Study Identifier: NCT03179930

Find a site near you

Start Over

Memorial Sloan Kettering Nassau

Uniondale, NY United States
  Connect »

Memorial Sloan Kettering Rockville Centre

Rockville Centre, NY United States
  Connect »